Cisplatin Increases Sensitivity of Human Leukemic Blasts to Triazene Compounds

REFERENCES

• Beretta G, Bonadonna G, Bajetta E, Tancini G, De Lena M, Azzarelli A, Umberto V. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcoma and Hodgkin's disease. Cancer Treat Rep 1976; 60: 205–11.
   PubMedGoogle Scholar
• Bono VH Jr. Studies on the mechanism of action of DTIC (NSC-45388) Cancer Treat Rep. 1976; 60: 141–8.
   Google Scholar
• D'Incalci M, Citti L, Taverna P, Catapano CV. Importance of DNA repair enzyme 06-alkyltransferase (AT) in cancer chemotherapy. 1988; Cancer Treat Rev 1988; 15: 279–92.
   PubMed Web of Science ®Google Scholar
• Meer L, Janzer RC, Kleihues P, Kolar GF. In vivo metabolism and reaction with DNA of the cytostatic agent 5-(3,3 - dimethyl-1 - triazeno ) -imidazole-4 - carboxamide (DTIC). Biochem Pharmacol 1986; 19: 3243-47.
   Google Scholar
• Karran P, Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 1992; 20: 2933–40.
   PubMed Web of Science ®Google Scholar
• Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Immunological alteration of leukemic cells in vivo after treat-ment with antitumor drugs. Proc Natl Acad Sci USA 1970; 66: 1089–95.
   PubMed Web of Science ®Google Scholar
• Grohman U, Ullrich SJ, Mage MG et al. Identification and immunogenic properties of an 89KDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. Eur J Immunol 1990; 20: 619–36.
   Google Scholar
• Giuliani A, D'Atri S, Franchi A, Tricarico M, Tentori L, Bonmassar E. Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds. In: Mancuso S ed. Achievements in Gynecology Basel, Karger 1989-90: 79-92. (Keller PJ ed. Contribution to Gynecology and Obstetrics; vol 18).
   Google Scholar
• Puccetti P, Romani L, Fioretti MC. Chemical xenoge-nization of experimental tumors. Cancer Metastasis Rev. 1987; 6: 93–111.
   PubMed Web of Science ®Google Scholar
• Bianchi R, Citti L, Beghetti R et al. 06-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylat-ing agents. Cancer Chemother Pharmacol 1992; 29: 277–82.
   Google Scholar
• D'Atri S, Tricarico M Margison GP et al. Antigenic changes of cancer cells following interaction with antitumor agents. In: Mihich E ed. Drug Resistance: mechanisms and reversal. Rome: John Libbey CIC, 1989: 271–87.
   Google Scholar
• Pegg AE, Byers TL. Repair of DNA containing 06-alkylguanine. FASEB J 1992; 6: 2302-10.
   Google Scholar
• Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for 06-alkylguanine. Proc Natl Acad Sci USA 1990; 87: 686–90.
   PubMed Web of Science ®Google Scholar
• Franchi A, Papa G, D'Atri S, Piccioni D, Masi M, Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study. Haematologica 1992; 77: 146–50.
   PubMed Web of Science ®Google Scholar
• Catapano CV, Broggini M, Erba E, et al. In vitro and in vivo methazolastone induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylni-trosoureas. Cancer Res 1987; 47: 4884–9.
   PubMed Web of Science ®Google Scholar
• Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385–6.
   PubMed Web of Science ®Google Scholar
• Roberts JJ, Knox RJ, Friedlos F, Lydall DA. DNA as the target for the cytotoxic and anti-tumor action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In McBrien DCH and Slater TF eds. Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford: IRL Press, 1986: 29–64.
   Google Scholar
• Wang L, Setlow RB. Inactivation of 06-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis 1989; 10: 1681–4.
   PubMed Web of Science ®Google Scholar
• Bennet JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Coopera-tive Group. Ann Intern Med 1985; 103: 620–5.
   Google Scholar
• Morten JEN and Margison GP. Increased 06-alkylgua-nine alkyltransferase activity in Chinese hamster V79 cells fol-lowing selection with chloroethylating agents. Carcinogenesis 1988; 9: 45–9.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Trey JE, Miller K, Berger NA. Comparison of 06-alkylguanine-DNA-alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986; 7: 745–9.
   PubMed Web of Science ®Google Scholar
• Margison GP, Cooper DP, Brennan J. Cloning of the E. Coli 06-methylguanine and methylphosphotriester methyl transferase gene using a functional DNA repair assay. Nucleic Acids Res 1985; 13: 1939–52.
   Google Scholar
• Welte, Platzer E, Lu L et al. Purification and biochem-ical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526–30.
   Google Scholar
• Lepri E, Liberati M, Portuese MG, Menconi E, Santucci A, Barzi A. In vitro chemosensitivity of newly diagnosed and relapsing acute non-lymphoid leukemia patients. Tumori 1991; 77: 25–7.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GRIP, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287–91.
   Google Scholar
• Brent TP. Inactivation of purified human 06-alkylgua-nine-DNA alkyltransferase by alkylating agents or alkylated DNA. Cancer Res 1986; 46: 2320–3.
   PubMed Web of Science ®Google Scholar
• Futscher BW, Micetich KC, Barnes DM, Fisher RI, Erickson LC. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun 1989; 1: 65–73.
   PubMedGoogle Scholar
• Gerson SL. Modulation of human lymphocyte 06-alkylguanine-DNA alkyltransferase by streptozotocin in vivo. Cancer Res 1989; 49: 3134–8.
   PubMed Web of Science ®Google Scholar
• Yarosh DB, Hurst Calderone S, Babich MA, Day RS. Inactivation of 06-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylni-trosourea by 06-methylguanine as a free base. Cancer Res 1986; 46: 1663–8.
   PubMed Web of Science ®Google Scholar
• Dolan ME, Moschel RC, Pegg AE. Depletion of mam-malian 06-alkylguanine-DNA alkyltransferase activity by 06-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 5368-72.
   Google Scholar
• Lee SM, Thatcher N, Margison GP. 06-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemus-tine. Cancer Res 1991; 51: 619–23.
   PubMed Web of Science ®Google Scholar
• Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. Eur J Cancer 1992; 28: 447–50.
   PubMed Web of Science ®Google Scholar
• Pieper RO, Futscher BW, Dong Q, Erickson LC. Effects of Streptozotocin/Bis-chloroethylnitrosourea combina-tion therapy on 06-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res 1991; 51: 1581–5.
   PubMed Web of Science ®Google Scholar